Study outcomes
The assessed outcomes in this meta-analysis comprised clinical
improvement of AR symptoms, use of rescue medication,
rhinoconjunctivitis-related quality of life and the occurrence of
adverse events. Studies, that assessed the safety and efficacy of
omalizumab regarding the aforementioned outcomes, were included in the
systematic review and meta-analysis regardless of the type and number of
outcomes.